📇 Rhumatologue · ST JULIEN EN GENEVOIS CEDE · (74) · Salarié

M Jonathan LIM

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
37 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
131.5 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ST JULIEN EN GENEVOIS CEDE (74)SalariéRPPS 10101925971

3 publications sur 5 ans

📊 Reconnaissance scientifique : 8/100📝 41 articles publiés🇫🇷 Publications académiques françaises (3)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy

Kidney international · 2025

📚 12 citations🎯 RCR 5.37🩺 Clinique

Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

📚 9 citations🎯 RCR 3.15🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Vaccination has been shown to attenuate the risk of postacute sequelae following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, no prior population-based studies have evaluated if updated bivalent boosters reduce risk of postacute sequelae following Omicron variant infection, versus ancestral vaccines. Methods National databases were utilized to construct a population-based cohort of adult individuals infected during Omicron-predominant transmission. Risk and excess burden (EB) of prespecified multiorgan new-incident diagnoses at 31–365 days post–SARS-CoV-2 infection were compared between individuals who received prior bivalent boosters and those boosted with ancestral messenger RNA (mRNA) vaccines, using competing-risks regression. Results A total of 1 080 348 vaccine-breakthrough infections after an ancestral mRNA booster were contrasted against 9824 vaccine-breakthrough infections following a bivalent mRNA booster. There was an estimated 37.8% (hazard ratio [HR], 0.62 [95 confidence interval {CI}, .53–.73]) decrease in risk and lower overall EB per 1000 (−28.73 [95% CI, −40.47 to −16.99]) of any postacute sequelae, as well as a 39.9% (HR, 0.62 [95% CI, .52–.73]) decrease in risk and lower EB (−22.95 [95% CI, −32.71 to −13.19]) of any postacute neurological sequelae, among individuals who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. Specifically, there was reduced risk of thrombotic disorders (HR, 0.54 [95% CI, .29–.99]), episodic neurological disorders (HR, 0.55 [95% CI, .43–.72]), movement disorders (HR, 0.57 [95% CI, .47–.70]), and autoimmune vasculitis (HR, 0.54 [95% CI, .29–.99]) 31–365 days postinfection among those who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. Conclusions Boosting with updated bivalent mRNA vaccines was associated with greater attenuation of risk for postacute sequelae following Omicron variant infection, compared with ancestral mRNA boosters.

Premature ovarian insufficiency: When ovaries retire early

Annals of the Academy of Medicine, Singapore · 2025

📚 5 citations🎯 RCR 2.30🔓 Open Access

Lire l'abstract Crossref ↓

Introduction: Premature ovarian insufficiency (POI) refers to loss of ovarian activity before the age 40 years. POI has significant detrimental effects on health (infertility, cardiovascular diseases, type 2 diabetes, reduced bone density, dementia), well-being and longevity. This is a practical toolkit for healthcare professionals (HCPs) looking after women with POI. Method: A workgroup comprising specialists in gynaecology, reproductive medicine, endocrinology, genetics and family medicine reviewed relevant guidelines and literature on POI to establish recommendations for the diagnosis and management of POI in Singapore. Result: A summary to assist HCPs manage POI was produced, outlining: (1) the aetiology and consequences of POI; (2) making the diagnosis; (3) hormone therapy (HT) prescribing options including for those with additional medical conditions; (4) counselling women with POI about HT; and (5) long-term management of POI. Conclusion: Timely diagnosis and management of POI is vital to prevent long-term adverse consequences, except infertility. Hormone therapy is the mainstay of treatment and there are no alternatives as effective. Contraindications are very few; estrogen-sensitive cancer is the main contraindication and caution in prescribing may be needed with established coexisting cardiovascular disease. Estrogen dosage is higher than when treating normal menopause, and as a result, the patient might require more progestogen for endometrial protection. Minimising cardiovascular risk factors by following a healthy lifestyle is important. POI is a significant public health issue and it is imperative that women have affordable access to appropriate HT. Large-scale research on POI in Asian women is needed.

Cookies & analyse de trafic

M Jonathan LIM

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (37) — classées par pathologie

Transversal14

Vraie vie / RWE4

Épidémiologie & registres3

Essai clinique3

Revue générale3

Goutte2

Revue / méta-analyse2

Biomarqueurs / Auto-Ac1

Biothérapies non-anti-TNF1

Case report / série1

Économie santé1

Gériatrie1

JAK inhibiteurs1

Maladie de Horton1

Ostéoporose1

Pédiatrie1

Pharmacovigilance1

Qualité de vie / PROMs1

Sjögren1

Datasets & protocoles partagés

Partager cette fiche